

REMARKS

I. The Restriction Requirement

The Examiner required restriction of claims 1-10, 14-16, 27-28 and 44 to one of the following groups:

Group I. Claims 1-3 and 10, drawn to a product of Formula (I), wherein R1-4 does not contain a heterocyclic group and AR is a substituted six membered heterocyclic group.

Group II. Claims 1-3 and 10, drawn to a product of Formula (I), wherein R1-4 does not contain a heterocyclic group and is not encompassed in Group I above.

Group III. Claim(s) 44, drawn to intermediate products.

Group IV-V. Claim(s) 15, drawn to a method of making products of Groups I or II respectively.

Group VI-VII. Claim(s) 4-9, 14 and 16, drawn to a method of using products of Groups I or II respectively for treating a mammal.

Group VIII-IX. Claim(s) 27 and 28, drawn to a method of using products of Groups I or II respectively for enhancing survival of cells.

Applicants wish to thank the Examiner for the courtesy extended the undersigned attorney during a telephonic interview which took place on April 30, 2007. During the interview, applicant's attorney acknowledged that the compound claims were restricted between Groups I and II. The compound claims were restricted as the outstanding restriction requirement indicated the compounds of Formula I did not form a single inventive concept under PCT Rule 13.1, because the core structure of Formula I was known in the art (See US patent 4,859,684). Applicant's attorney noted that the '684 patent was directed to a different utility than the instant TPO agonist compounds. And as such, Groups VI and VII, could be grouped together into a single group because the method of treating thrombocytopenia using a compound of Formula I relates to a single inventive concept under PCT Rule 13.1.

It was agreed that the restriction requirement should be changed to permit method of treatment Groups VI and VII to be combined into a single group. It was also agreed that the eight compounds prepared in the application (the compounds of Examples 1 to 8) could also be part of this group. All other groups were to remain as in the original restriction requirement.

Applicants hereby elect, without traverse, the combined grouping of the methods in Groups VI and VII and the compounds of Examples 1 to 8.

For the convenience of the Examiner and in order to advance the prosecution, the previously pending claims have been canceled and replaced by newly added claims 45 to 55. Claims 45 to 55 are directed to applicant's elected invention, the method of treating thrombocytopenia using a compound of Formula I and the compounds of Examples 1 to 8.

The cancellation of the original claims and the addition of newly added claims 45 to 55, is believed to be full and complete response to the outstanding Restriction Requirement. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned attorney at the number indicated below.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicant
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610)270-5090
n:\wjd\TPO\IP51399\Restriction Req.doc